跳转至内容
Merck
CN
  • Lipopolysaccharide-Induced Increase in Intestinal Epithelial Tight Permeability Is Mediated by Toll-Like Receptor 4/Myeloid Differentiation Primary Response 88 (MyD88) Activation of Myosin Light Chain Kinase Expression.

Lipopolysaccharide-Induced Increase in Intestinal Epithelial Tight Permeability Is Mediated by Toll-Like Receptor 4/Myeloid Differentiation Primary Response 88 (MyD88) Activation of Myosin Light Chain Kinase Expression.

The American journal of pathology (2017-11-22)
Meghali Nighot, Rana Al-Sadi, Shuhong Guo, Manmeet Rawat, Prashant Nighot, Martin D Watterson, Thomas Y Ma
摘要

Lipopolysaccharides (LPSs) are a major component of the Gram-negative bacterial cell wall and play an important role in mediating intestinal inflammatory responses in inflammatory bowel disease. Although recent studies suggested that physiologically relevant concentrations of LPS (0 to 1 ng/mL) cause an increase in intestinal epithelial tight junction (TJ) permeability, the mechanisms that mediate an LPS-induced increase in intestinal TJ permeability remain unclear. Herein, we show that myosin light chain kinase (MLCK) plays a central role in the LPS-induced increase in TJ permeability. Filter-grown Caco-2 intestinal epithelial monolayers and C57BL/6 mice were used as an in vitro and in vivo intestinal epithelial model system, respectively. LPS caused a dose- and time-dependent increase in MLCK expression and kinase activity in Caco-2 monolayers. The pharmacologic MLCK inhibition and siRNA-induced knock-down of MLCK inhibited the LPS-induced increase in Caco-2 TJ permeability. The LPS increase in TJ permeability was mediated by toll-like receptor 4 (TLR-4)/MyD88 signal-transduction pathway up-regulation of MLCK expression. The LPS-induced increase in mouse intestinal permeability also required an increase in MLCK expression. The LPS-induced increase in intestinal permeability was inhibited in MLCK-/- and TLR-4-/- mice. These data show, for the first time, that the LPS-induced increase in intestinal permeability was mediated by TLR-4/MyD88 signal-transduction pathway up-regulation of MLCK. Therapeutic targeting of these pathways can prevent an LPS-induced increase in intestinal permeability.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
L-(−)-二硫苏糖醇, ≥95% (titration)
Sigma-Aldrich
单克隆抗肌球蛋白轻链激酶 小鼠抗, clone K36, ascites fluid
Supelco
Discovery® Glycan SPE Tube, bed wt. 500 mg, volume 6 mL, pk of 30
Supelco
Discovery® Glycan SPE Tube, bed wt. 250 mg, volume 3 mL, pk of 54
Supelco
Discovery® Glycan SPE Bulk Packing, pkg of 50 g
Sigma-Aldrich
抗-磷酸肌球蛋白轻链(pSer19) 兔抗, affinity isolated antibody, buffered aqueous glycerol solution
Supelco
Discovery® Glycan SPE Tube, 5 g, volume 60 mL, pk of 16
Supelco
Discovery® Glycan SPE Tube, bed wt. 1 g, volume 12 mL, pk of 20